On November 24, 2020 the Spanish start-up, specialized in developing a technology to transport drugs to the brain, reported the company is seeking up to three million euros to reach the clinical trial (Press release, Gate2Brain, NOV 24, 2020, View Source [SID1234641077]). The CEO of Gate2Brain, Meritxell Teixidó, explains to PlantaDoce that the company plans to open a financing round in April 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The start-up develops a technology to transport drugs to the brain . The company will use the funds to advance therapeutic tests since, although it has identified the drug to deliver to this organ according to the group of pediatric brain tumors, it must improve transport.

In this way, the company would increase the effectiveness of brain disease treatments with its technology, while reducing side effects. Teixidó assures that the objective is "to validate the platform and for a pharmaceutical company to look at it to acquire the company . "

Gate2Brain seeks to improve the effectiveness of brain disease treatments

The company is a spin off of the Barcelona Biomedical Research Institute, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute of the Sant Joan de Déu Hospital (SJD). The company has its headquarters in the Barcelona Science Park.

Gate2Brain envisions its technology will allow drugmakers to recover promising drugs that don’t make it to market because they can’t be transported to the brain. The company’s CEO states that "98% of drug candidates are discarded because they do not pass the barrier and our technology would allow investment in these drugs not to be left in a corner." The company is in contact with some pharmaceutical companies .

The start-up plans to open a financing round of between two million euros and three million euros in April 2021 . Gate2Brain estimates to begin the clinical trial in 2023. The company has carried out some tests at the Sant Joan de Déu Hospital in Barcelona and has observed that its technology would have applicability in various tumors.

Gate2Brain has received funding from the Botín Foundation

Gate2Brain has received support from the Botín Foundation’s Mind The Gap Program, which invests up to half a million euros per project . The start-up obtained online research support from the CaixaImpulse program of the La Caixa Foundation and funding from the Agency for Management and University Research Grants (Agaur) in the Knowledge Industry Grants call.

The company currently has five workers. Gate2Brain, founded by Teixidó and three other entrepreneurs, has Marc Ramis, CEO of Ninevah Therapeutics, as an advisor. The founders control the majority of the company’s shareholders.

On November 24, 2020 The Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the "Company") reported that it has prepared a prospectus (the "Prospectus") relating to the issue of new shares with preferential rights for existing shareholders of approximately SEK 236 million (the "Rights Issue"), which was resolved on by the Board of Directors on 16 November 2020, pursuant to the authorization granted by the extraordinary general meeting held on 13 November 2020 (Press release, Scandion Oncology, NOV 24, 2020, View Source,c3242441 [SID1234574541]). The Prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). Today, the Company also announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Not for publication, distribution or announcement, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction in which publication, distribution or announcement of this press release is unlawful or is subject to legal restrictions other than those required by Swedish law.

Publication of Prospectus

The Prospectus has been prepared relating to the Rights Issue and has today, 24 November 2020, been approved by and registered with the Swedish Financial Supervisory Authority. The Prospectus, containing full terms and conditions, and application forms are available on the Company’s website, (View Source). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website, (View Source).

Summary of the Rights Issue

The Rights Issue will, upon full subscription, provide the Company with approximately SEK 236 million before costs related to the rights issue.
Those who on the record date, 24 November 2020, are registered as shareholders of Scandion Oncology will have preferential right to subscribe for new shares in the Rights Issue. For one (1) existing share held on the record date the holder receives one (1) subscription right. Two (2) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of SEK 22 per share.
The subscription period for subscription of new shares runs from 26 November 2020 up to and including 10 December 2020.
The Rights Issue is covered by approximately 14 per cent subscription undertakings, whereof approximately 4.4 million SEK by insiders. In addition, the Company has received approximately 86 per cent guarantee commitments from external professional investors and is thus fully guaranteed. No compensation is paid for provided subscription undertakings.
Preliminary timetable for the Rights Issue

20 November 2020 Last trading day in Scandion Oncology’s shares including the right to receive subscription rights in the Rights Issue
23 November 2020 First trading day in Scandion Oncology’s shares excluding the right to receive subscription rights in the Rights Issue
24 November 2020 The record date for the Rights Issue
26 November – 10 December 2020 Subscription period of the Rights Issue
26 November – 8 December 2020 Trading in subscription rights on Spotlight Stock Market
26 November – Until conversion of BTAs to new shares Trading in BTAs ongoing until the Danish Business Authority has registered the Rights Issue and BTAs are converted to shares
Around 15 December 2020 The expected date for the announcement of the outcome in the Rights Issue
Around 11 January 2021 Trading in new shares commences

Change of listing to Nasdaq First North Growth Market Sweden

The Board of Directors of Scandion Oncology intends, as a subsequent step following the Rights Issue, to make a list change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden.

Advisors

Vator Securities is financial adviser. and Advokatfirman Schjødt (as to Swedish law) and Plesner Advokatpartnerselskab (as to Danish law) are legal advisers to the Company in connection with the Rights Issue.

On November 24, 2020 AbbVie (NYSE: ABBV) reported that it will participate in the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2 at 1:40 p.m. CT and the Piper Sandler Virtual Healthcare Conference on Thursday, December 3 at 10 a.m. CT. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present at both conferences (Press release, AbbVie, NOV 24, 2020, View Source [SID1234571651]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of each presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the sessions will be available later that day.

On November 24, 2020 Laminar Pharma reported that closer and closer to our stock market launch (Press release, Laminar Pharma, NOV 24, 2020, View Source [SID1234574077]). That’s why we launched a funding round this month to increase investment in research staff and advance the development of clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This operation raised more than 1.2 million euros

The financing round was launched on October 30 with the aim of raising 1.2 million euros and is currently available on the Fellow Funders Crowd Investment platform. In the first two weeks, thanks to the trust of numerous investors, more than one million euros had been raised, which is equivalent to 92% of the target set and now, before the month ends the target will be met. In addition to this main source of financing, which is private investment, we have received support from the Spanish government, Spain’s regional governments and the European Commission.

Pablo Escribá, our CEO, has a positive outlook: "We are happy about exceeding the planned target, as we did in the round at the end of last year. Currently at Laminar Pharma we hold patents for 8% of all drugs under development by Spanish biotechnology companies in our country, according to the pipeline of the Spanish Association of Bio-companies (ASEBIO) and we hope to grow in valuation as we advance in the clinical research stages of our drugs undergoing development. The company plans to request marketing authorization from regulatory agencies in two years, with the aim of announcing our first market launch in 2023."

Fellow Funders partner Mariano Colmenar is satisfied with the operation, which is run by his own collective financing platform, authorized and supervised by the National Securities Market Commission (CNMV) since 2016. "We have shown that investors see a promising future in the biotechnology sector, anticipating good benefits. The pharmaceutical market is a long-term market, since years of research and clinical trials are necessary before the products can safely be launched to market." Fellow Funders collaborates with Nowture, the first comprehensive ecosystem that catalyzes and drives the growth of the Biotechnology and Life Sciences sector in Spain, offering a model of specialized and customized services, with national and European science and business experts. Nowture company, was born at the end of 2020 as the first comprehensive investment and promotion ecosystem for companies in the Biotechnology and life sciences sector in Spain. Nowture has been present in Laminar Pharma’s capital since 2019, to accompany it in the optimization and execution of the product development plan, in the corporate financing strategy and in its preparation to apply to join BME Growth.

On November 24, 2020 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that management will present at two upcoming virtual investor conferences in December (Press release, Protara Therapeutics, NOV 24, 2020, View Source [SID1234573139]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 32nd Annual Virtual Healthcare Conference
Evercore ISI 3rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020 at 12:10pm ET
A webcast of the live Evercore presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source A replay of the pre-recorded Piper fireside chat is currently available on the Company’s website. The webcasts will be archived on the Company’s website for 90 days following the presentation.